WO2016060426A1 - 백편두 추출물을 유효성분으로 포함하는 비알콜성 지방간질환의 예방 또는 개선용 조성물 - Google Patents
백편두 추출물을 유효성분으로 포함하는 비알콜성 지방간질환의 예방 또는 개선용 조성물 Download PDFInfo
- Publication number
- WO2016060426A1 WO2016060426A1 PCT/KR2015/010745 KR2015010745W WO2016060426A1 WO 2016060426 A1 WO2016060426 A1 WO 2016060426A1 KR 2015010745 W KR2015010745 W KR 2015010745W WO 2016060426 A1 WO2016060426 A1 WO 2016060426A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- fatty liver
- liver disease
- alcoholic fatty
- alcoholic
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 100
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 244000046095 Psophocarpus tetragonolobus Species 0.000 title claims abstract description 26
- 239000004480 active ingredient Substances 0.000 title claims abstract description 24
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 title abstract 3
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 235000009200 high fat diet Nutrition 0.000 claims description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 208000019695 Migraine disease Diseases 0.000 claims description 35
- 206010027599 migraine Diseases 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 235000007007 Dolichos lablab Nutrition 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 18
- 208000010706 fatty liver disease Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 210000005228 liver tissue Anatomy 0.000 claims description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 13
- 208000004930 Fatty Liver Diseases 0.000 claims description 12
- 239000003674 animal food additive Substances 0.000 claims description 12
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 12
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 10
- 230000006872 improvement Effects 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 230000001476 alcoholic effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229960003415 propylparaben Drugs 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 3
- 240000007472 Leucaena leucocephala Species 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- 239000000378 calcium silicate Substances 0.000 claims description 3
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 3
- 235000012241 calcium silicate Nutrition 0.000 claims description 3
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 229920001971 elastomer Polymers 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229940014259 gelatin Drugs 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 235000012222 talc Nutrition 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000000022 bacteriostatic agent Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims description 2
- 229960001714 calcium phosphate Drugs 0.000 claims description 2
- 229960003340 calcium silicate Drugs 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000008223 sterile water Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 abstract description 16
- 208000014018 liver neoplasm Diseases 0.000 abstract description 16
- 230000007935 neutral effect Effects 0.000 abstract description 4
- 238000009825 accumulation Methods 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 235000021588 free fatty acids Nutrition 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 35
- 150000003626 triacylglycerols Chemical class 0.000 description 29
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
- 238000010186 staining Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 10
- 210000000577 adipose tissue Anatomy 0.000 description 10
- 229960004592 isopropanol Drugs 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- MPDGHEJMBKOTSU-VOPRYAMFSA-N (2s,4as,6as,6br,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylic acid Chemical compound C([C@H]1C2=CC(=O)C34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CCC1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-VOPRYAMFSA-N 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 229940049964 oleate Drugs 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 6
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 6
- 206010073069 Hepatic cancer Diseases 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004490 abdominal subcutaneous fat Anatomy 0.000 description 6
- 229940069765 bean extract Drugs 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 201000010063 epididymitis Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 6
- 229940010454 licorice Drugs 0.000 description 6
- 229940096421 milk thistle extract Drugs 0.000 description 6
- 235000020727 milk thistle extract Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 244000066764 Ailanthus triphysa Species 0.000 description 5
- 241000202807 Glycyrrhiza Species 0.000 description 5
- 244000046052 Phaseolus vulgaris Species 0.000 description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002417 nutraceutical Substances 0.000 description 4
- 235000021436 nutraceutical agent Nutrition 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 235000020712 soy bean extract Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000070 MTS assay Toxicity 0.000 description 3
- 238000000719 MTS assay Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 240000004922 Vigna radiata Species 0.000 description 2
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 2
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 229940042472 mineral oil Drugs 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- -1 pH adjusters Substances 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- CQAIPTBBCVQRMD-UHFFFAOYSA-L dipotassium;phosphono phosphate Chemical compound [K+].[K+].OP(O)(=O)OP([O-])([O-])=O CQAIPTBBCVQRMD-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Polymers [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Definitions
- the present invention relates to a nutraceutical composition and pharmaceutical composition for the prevention or improvement of non-alcoholic fatty liver disease comprising the extract of Dolichos lablab Linne as an active ingredient.
- liver disease in Korea The mortality rate of liver disease in Korea is very high, with 23.5 deaths per 100,000 population, the number one cause of death in the 40s (41.1 / 100,000), the second cause of death in the 50s (72.4 / 10 million), and the third cause of death in the 30s. Liver disease is the leading cause of death among the Korean middle-aged population.
- fatty liver refers to a phenomenon in which neutral fat, which does not exist in normal cells, appears abnormally deposited in liver cells. About 5% of normal liver is composed of fatty tissue, and triglycerides, fatty acids, phospholipids, cholesterol, and cholesterol esters are the major components of fat, but once fatty liver occurs, most of the components are replaced with triglycerides. If more than 5% of the weight of the liver is diagnosed as fatty liver. Fatty liver deteriorates and the mass of fat in the hepatocytes is pushed to important components of the cells, including the nucleus, to one side, reducing the function of the hepatocytes. This leads to impaired circulation of blood and lymph in the liver. If this happens, the liver cells can not receive adequate oxygen and nutrition, liver function is reduced.
- Non-alcoholic fatty liver disease is not defined as alcohol damage to liver, but is defined as fatty acids accumulated in the parenchymal cells of the liver more than 5% in the form of triglycerides. Pathologically, it is classified as simple steatosis and steatohepatitis with inflammation, which can lead to serious liver diseases such as hepatitis, liver fibers, and cirrhosis of the liver for a long time. In Korea, the incidence of nonalcoholic liver disease is increasing due to lifestyle changes.
- Dolichos lablab Linne also known as Swallow bean, Magpie bean or Small bean ( ⁇ )
- leaves are exudative and regenerated
- regenerated leaflets are small, triangular egg-shaped
- leaflets are broad ovate with sharp leaves and near stems.
- the leaf on is broad wedge or stalk, with flat edges and hairs on both sides.
- the flowers are butterfly-shaped and white, and the seeds are white to 2-5.
- the present invention was derived by the above-mentioned demands, and completed the present invention by confirming that the content of triglycerides in the hepatocytes treated with the white migraine extract which is the active ingredient of the present invention is effectively reduced.
- the present invention provides a health functional food composition for the prevention or improvement of non-alcoholic fatty liver disease comprising a white migraine extract as an active ingredient.
- the present invention provides a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease comprising a white migraine extract as an active ingredient.
- the present invention provides a composition for reducing body weight or blood sugar elevated by a high-fat diet containing the extract of Dolichos lablab Linne as an active ingredient.
- the present invention also provides a method for preventing or treating non-alcoholic fatty liver disease, comprising administering an extract of Dolichos lablab Linne to an individual.
- the present invention also provides a veterinary composition for the prevention or treatment of fatty liver disease in animals other than humans including the extract of Dolichos lablab Linne as an active ingredient.
- the present invention provides a feed additive for the prevention or improvement of fatty liver disease in animals comprising the extract of Dolichos lablab Linne as an active ingredient.
- the present invention relates to a nutraceutical composition for the prevention or improvement of non-alcoholic fatty liver disease (NAFLD) comprising a white migraine extract as an active ingredient
- the composition of the present invention is the accumulation of triglycerides By inhibiting it can be usefully used as a health functional food and medicine for the prevention or improvement of non-alcoholic fatty liver disease.
- Figure 2 is a result of confirming the degree of neutral fat produced by treating 1 mM free fatty acid in hepatic cancer cell line (HepG 2 ) reduced by the licorice phytosome (18 beta-glycyrrhetinic acid), a positive control group, after staining with Nile red
- the figure confirms the fat content.
- the control was treated with 5% (w / v) BSA solution without free fatty acids.
- 3 is a result of confirming the degree of triglycerides produced by treating 1 mM free fatty acid in hepatic cancer cell line (HepG 2 ) by licorice phytosome (18 beta-glycyrrhetinic acid) as a positive control group after oil red o staining, This is the result of obtaining an image of triglycerides.
- the control was treated with 5% (w / v) BSA solution without free fatty acids.
- Figure 4 is a result of Nile staining assay confirming the degree of triglyceride produced by treating 1 mM free fatty acid in hepatic cancer cell line (HepG 2 ) is reduced by the white migraine hydrothermal extract.
- the control was treated with 5% (w / v) BSA solution without free fatty acids.
- FIG. 5 is an image of triglycerides obtained from an oil red o staining assay confirming the degree to which triglycerides produced by treating 1 mM free fatty acid in a hepatic cancer cell line (HepG 2 ) are reduced by H. pylori extract.
- the control was treated with 5% (w / v) BSA solution without free fatty acids.
- Figure 6 is a result of Nile red staining assay confirming the degree of triglyceride produced by treating 1 mM free fatty acid in liver cancer cell line (HepG 2 ) by the baekpandu ethanol extract. The control was treated with 5% (w / v) BSA solution without free fatty acids.
- FIG. 7 is an image of triglycerides obtained from an oil red o staining assay confirming the degree of decrease in triglycerides produced by treating 1 mM free fatty acid in hepatic cancer cell line (HepG 2 ) by a white migraine ethanol extract. The control was treated with 5% (w / v) BSA solution without free fatty acids.
- FIG. 8 is an MTS assay result carried out to confirm the cytotoxicity of the baekryeok hydrothermal extract according to an embodiment of the present invention.
- the control was treated with 5% (w / v) BSA solution without free fatty acids.
- Figure 9 is a Nile red dye assay results comparing the degree of reducing the content of triglycerides of soybean extract, frost extract, mung bean extract and pea extract as a control and the white hot water extract according to an embodiment of the present invention.
- the control group was treated with 5% (w / v) BSA solution containing no free fatty acids, and the relative values based on the content of triglycerides when 100 mM were treated with 1 mM free fatty acids.
- Figure 10 is the result of confirming the effect of the white migraine hot water extract according to an embodiment of the present invention on the increase in body weight (A) and the increase in liver tissue weight (B) of the mouse by a high fat diet.
- CON is a normal control group
- HFD is a high-fat diet in which fatty liver is ingested by a high-fat diet
- HFD + DLL-Ex combines a high-fat diet with 25, 50, 100 (mg / kg / day) white migraine hydrothermal extract.
- Intake group is a normal control group
- HFD is a high-fat diet in which fatty liver is ingested by a high-fat diet
- HFD + DLL-Ex combines a high-fat diet with 25, 50, 100 (mg / kg / day) white migraine hydrothermal extract.
- Intake group is a normal control group
- Figure 11 shows the total fat (A), abdominal subcutaneous fat (B), epididymal fat of mice with high-fat diet of 25, 50, 100 (mg / kg / day) of Baekjeok hot water extract according to an embodiment of the present invention
- This is the result of confirming the effect on the weight of tissue (C) and small intestine adipose tissue (D).
- ## indicates that the total fat (A), abdominal subcutaneous fat (B), epididymal fat tissue (C) and small intestinal adipose tissue (D) of the high fat diet group (HFD) significantly increased compared to the normal group (CON).
- Figure 13 is a 25, 50, 100 (mg / kg / day) of white migraine hot water extract according to an embodiment of the present invention in the blood due to a high fat triglycerides (A), total cholesterol (B), low density lipoprotein ( C), whether the increase in free fatty acids (D) is confirmed.
- A high fat triglycerides
- B total cholesterol
- C low density lipoprotein
- D free fatty acids
- ## means a significant increase in triglyceride (A), total cholesterol (B), low density lipoprotein (C) and free fatty acid (D) in the blood of the high fat diet group (HFD) compared to the normal group (CON) ( p ⁇ 0.01), *, ** are triglycerides (A) and total cholesterol (B) in the experimental group (HFD + DLL-Ex) with high-fat dietary intake and H2D extracts compared to the high-fat diet (HFD). ), Low density lipoprotein (C), free fatty acid (D) means a significant decrease.
- M100 is a positive control, a group administered with milk thistle extract (100mg / kg / day) with a high fat diet.
- Figure 14 is a result of confirming whether 25, 50, 100 (mg / kg / day) of the white migraine hot water extract in accordance with an embodiment of the present invention reduces the increase in fasting blood glucose due to a high fat diet.
- ## means that the fasting blood sugar level of the high fat diet group (HFD) is significantly increased compared to the normal group (CON) (p ⁇ 0.01), and *, ** are the high fat diet intake and back migraine compared to the high fat diet group (HFD).
- FFD + DLL-Ex the experimental group
- M100 is a positive control, a group administered with milk thistle extract (100mg / kg / day) with a high fat diet.
- the present invention relates to a nutraceutical composition for the prevention or improvement of non-alcoholic fatty liver comprising the extract of Dolichos lablab Linne as an active ingredient.
- the white bean extract may be used a conventional extraction solvent known in the art.
- Preferred extraction solvents include water, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms (e.g. methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol and normal-butanol), and the lower alcohols with water Mixed solvents, acetone, ethyl acetate, chloroform, 1,3-butylene glycol, hexane, diethyl ether, or butyl acetate are used, more preferably water or ethanol, even more preferably water.
- the water is added by a volume of 5 to 10 times with respect to the weight of the bag migraine and is extracted by heating at 90 to 110 ° C. for 2 to 3 hours.
- the extraction solution is preferably filtered through filter paper and then lyophilized, but not always limited thereto.
- 80% ethanol is added in a volume of 5 to 10 times the weight of the white migraine, and it is extracted by dipping for 22 to 24 hours at a room temperature of 20 to 25 ° C.
- the extraction solution is preferably filtered through filter paper and then lyophilized, but not always limited thereto.
- the white migraine extract is characterized by reducing the triglyceride content of the liver tissue, the non-alcoholic fatty liver disease is characterized in that any one selected from non-alcoholic simple fatty liver, non-alcoholic fatty hepatitis and non-alcoholic cirrhosis It is not limited to this.
- the white bean extract is preferably 0.1 to 10% by weight based on the total weight of the composition, but is not limited thereto, and the composition of the present invention may be added to foods for the purpose of preventing or improving nonalcoholic fatty liver disease.
- the health functional food is not particularly limited to all, such as health functional food, nutritional supplements, nutritional supplements, pharmafood (health food), health food, nutraceutical, designer food, food additives, etc. It may be in the form of food, preferably meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, dairy products including other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes.
- the method of addition is suitably used according to a conventional method, and the addition amount can be suitably determined according to the purpose of use (prevention, health or therapeutic treatment).
- composition of the present invention may further include various components other than the active ingredient, but these various components are not particularly limited thereto, but preferably various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and Salts, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. It may also contain pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks to add palatability and / or functionality, and these ingredients may be used independently or in combination.
- the present invention also relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease comprising a white migraine extract as an active ingredient.
- the white bean extract may be used a conventional extraction solvent known in the art.
- Preferred extraction solvents include water, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms (e.g. methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol and normal-butanol), and the lower alcohols with water Mixed solvents, acetone, ethyl acetate, chloroform, 1,3-butylene glycol, hexane, diethyl ether, or butyl acetate are used, more preferably water or ethanol, even more preferably water.
- the water is added by a volume of 5 to 10 times with respect to the weight of the bag migraine and is extracted by heating at 90 to 110 ° C. for 2 to 3 hours.
- the extraction solution is preferably filtered through filter paper and then lyophilized, but not always limited thereto.
- 80% ethanol is added in a volume of 5 to 10 times the weight of the white migraine, and it is extracted by dipping for 22 to 24 hours at a room temperature of 20 to 25 ° C.
- the extraction solution is preferably filtered through filter paper and then lyophilized, but not always limited thereto.
- the white migraine extract is characterized by reducing the triglyceride content of liver tissue, the non-alcoholic fatty liver disease is characterized in that any one selected from non-alcoholic simple fatty liver, non-alcoholic fatty hepatitis and non-alcoholic cirrhosis It is not limited to this.
- the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are conventionally used in the preparation, saline solution, sterile water, Ringer's solution, buffered saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol, lactose, dex Straw, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, syrups, methyl cellulose, methylhydroxybenzoate, propyl Hydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
- the pharmaceutical composition of the present invention may further include antioxidants, buffers, bacteriostatic agents, diluents, surfactants, binders, lubricants, wetting agents, sweetening agents, flavoring agents, emulsifiers, suspending agents or preservatives in addition to the above components.
- the pharmaceutical composition of the present invention may be administered orally or parenterally, and preferably applied by oral administration. Suitable dosages of the pharmaceutical compositions of the present invention may be prescribed in various ways depending on factors such as formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to response of the patient. Can be.
- the dosage of the pharmaceutical composition of the present invention is preferably 0.001-100 mg / kg on an adult basis.
- compositions of the present invention may be prepared in unit dosage form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporation into a multi-dose container.
- the formulation may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of extracts, powders, powders, granules, tablets or capsules, and may further comprise dispersants or stabilizers.
- the present invention also relates to a composition for reducing body weight or blood sugar, which is elevated by a high fat diet containing the extract of Dolichos lablab Linne as an active ingredient.
- the present invention also relates to a method for preventing or treating non-alcoholic fatty liver disease, comprising administering an extract of Dolichos lablab Linne to an individual.
- the subject includes all animals including humans with the possibility of nonalcoholic fatty liver disease, including patients with nonalcoholic fatty liver disease.
- the present invention relates to a veterinary composition for the prevention or treatment of fatty liver disease in animals other than humans including the extract of Dolichos lablab Linne as an active ingredient.
- Veterinary compositions comprising the extract of Dolichos lablab Linne of the present invention may further comprise suitable excipients and diluents according to conventional methods.
- Excipients and diluents that may be included in the veterinary composition comprising the extract of Dolichos lablab Linne of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia Rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, Stearyl alcohol, liquid paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben and mineral oil.
- the veterinary composition comprising the extract of Dolichos lablab Linne according to the present invention may further include a filler, an anticoagulant , a lubricant, a humectant, a spice, an emulsifier, a preservative, and the like.
- Formulations may be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to the animal, wherein the formulation is a powder, granule, tablet, capsule, suspension, emulsion, solution , Syrups, aerosols, soft or hard gelatin capsules, suppositories, sterile injectable solutions, sterile external preparations, and the like.
- the veterinary composition according to the present invention may vary depending on the age, sex and weight of the animal, but may be administered in an amount of 0.1 to 100 mg / kg once or several times a day, and the dosage may be a route of administration, a degree of disease, It may increase or decrease depending on gender, weight, age, and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.
- the present invention relates to a feed additive for the prevention or improvement of fatty liver disease in animals comprising the extract of Dolichos lablab Linne as an active ingredient.
- the feed additive may be in the form of a high concentrate, powder or granules containing 20 to 90% by weight of the extract of Dolichos lablab Linne.
- the feed additive of the present invention includes organic acids such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid, phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate and polyphosphate (polyphosphate), polyphenols, catechins and alpha. It may further include one or more selected from natural antioxidants such as tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, phytic acid.
- organic acids such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid, phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate and polyphosphate (polyphosphate), polyphenols, catechins and alpha. It may further include one or more selected from natural antioxidants such as tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, phytic acid.
- Animal feed additives containing the extract of Dolichos lablab Linne of the present invention and feed containing them are amino acids, inorganic salts, vitamins, antibiotics, antibacterial substances, antioxidants, antifungal enzymes, digestive and absorption enhancers, It can be used with materials such as growth promoters, disease prevention agents and the like.
- the feed additive may be administered to the animal alone in combination with other feed additives in an edible carrier.
- the feed additives can be easily administered as a top dressing or directly mixed into animal feed or separately from the feed, in a separate oral formulation, by injection or transdermal or in combination with other ingredients.
- single or divided daily dosages can be used as is well known in the art.
- dosage forms of the extracts as is well known in the art, can be prepared in immediate release or sustained release formulations in combination with non-toxic pharmaceutically acceptable edible carriers.
- Such edible carriers may be solid or liquid, for example corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol.
- the dosage form of the extract may be tablets, capsules, powders, torokies or sugar-containing tablets or top dressings in microdisperse form.
- a liquid carrier it may be in the form of soft gelatin capsules or syrups or liquid suspensions, emulsions or solutions.
- the dosage form may contain auxiliaries such as preservatives, stabilizers, wetting or emulsifying agents, solution promoters and the like.
- the animal feed comprising the Dolichos lablab Linne extract as a feed additive may be any protein-containing organic cereal meal commonly used to meet the dietary needs of the animal. Such protein-containing flours typically consist mainly of corn, soy flour, or corn / bean flour mixtures.
- the feed additive may be used by adding to the animal feed by dipping, spraying or mixing.
- the veterinary composition or feed additive of the present invention can be applied to the diet of a companion animal.
- Oil Red O 0.35 g of Oil Red O was prepared by dissolving in 100 ml of isopropanol, and then filtered using a 0.2 ⁇ m filter and stored at room temperature.
- Liver cancer cell line (HepG 2 ) was purchased from the American Type Culture Collection (ATTC). Liver cancer cell line (HepG 2 ) was cultured in Dulbecco's modified Eagle's medium (DMEM) medium containing 10% FBS, 1% penicillin-streptomycin. The cells were cultured in a 5% CO 2 incubator at 37 ° C., and the cultured cells were tested by dispensing a predetermined number of cells (3 ⁇ 10 4 cells / 500 ⁇ l well) in a 24-well plate.
- DMEM Dulbecco's modified Eagle's medium
- the cells were used when the cells reached 75% saturation (confluence) after the 24 wells completely attached and shaped the cells.
- a 0.1 M NaOH solution was prepared at 70 ° C. as a solvent, filtered using a 0.2 ⁇ m filter, and then sterilized.
- ddH 2 O Tertiary distilled water
- each fatty acid prepared in 1) was 5 mM using 5% (w / v) BSA solution containing no free fatty acid dissolved in tertiary distilled water prepared in 2) as a solvent. 10 ml of a fatty acid stock solution was prepared. 100 mM palmitate and 100 mM oleate stock solution prepared in 1) was taken with 165 ⁇ l (1.65 mM) of palmitate and 330 ⁇ l (3.3 mM) of oleate, and 9,505 ⁇ l of 5% (w) / v) vortexing while dropping the drops of BSA solution. Thereafter, the mixture was cooled to room temperature, and then filtered through a 0.2 ⁇ m filter (the prepared mixed solution is stable even if stored at -20 ° C. for 3 to 4 weeks).
- the final volume is mixed with a growth medium containing 495 ⁇ l of NaOH in Dulbecco's modified Eagle's medium (DMEM) containing 10 ml of 5% FFA-free BSA solution + 40 ml of 0.5% FBS / 1% penicillin-streptomycin. Prepared to 50 ml.
- DMEM Dulbecco's modified Eagle's medium
- Licorice phytosome (18 beta-glycyrrhetinic acid) of 10 to 100 ⁇ M was used as a positive control.
- liver cancer cell line HepG 2
- FFA free fatty acid
- adipored solution prepared by dissolving 300 ⁇ l of AdipoRed in 10 ml of PBS
- 500 ⁇ l / well was dispensed and reacted by shaking gently for 15 minutes at room temperature. . Plates were stored wrapped in aluminum foil to minimize photobleaching of the dye during this process.
- reaction was completed, it was applied to a spectrophotometer and the excitation wavelength was measured at 485 nm and emission wavelength 572 nm.
- liver cancer cell line (HepG 2 ) After removing the medium from the liver cancer cell line (HepG 2 ), the cells were washed with 0.5 ml of PBS buffer, and PBS buffer was completely removed. Thereafter, 0.5 ml of 10% formalin was added at room temperature and incubated for 10 minutes.
- the cells were incubated for at least 1 hour (the cells can be stored in the formalin solution for several days before staining, and wrapped in aluminum foil and parafilm to dry the cells). Should be avoided).
- Oil Red O solution 0.5 ml was added to the dried cells and incubated at room temperature for 10 minutes, after which the Oil Red O solution was removed and immediately washed by adding ddH 2 O. The following was repeated four times. Debris of the staining solution was removed as much as possible, after which an image was obtained using a fluorescence microscope.
- Oil Red O staining solution dissolved in 100% isopropanol in dry state was added thereto and gently incubated for 10 minutes. At this time, the oil red O (Oil Red O) stained well so that the pipette up and down to mix, and then transferred to a 96-well plate and measured the OD at 500nm. The OD value of 100% isopropanol was measured and used as the reference value (zero point).
- liver cancer cell line HepG 2
- NAFLD non-alcoholic fatty liver
- Hepatocarcinoma cell line (HepG 2 ) was treated with free fatty acids mixed with oleic acid and palmitic acid at a weight ratio of 2: 1 at concentrations of 0.125, 0.25, 0.5, and 1.0 mM, and then the change in the content of triglycerides was tested by nile dyeing assay. As a result of confirming with the oil red o staining assay, it was confirmed that the content of triglycerides increased in proportion to the increase in the concentration of free fatty acids (Fig. 1).
- the degree of decrease in the content of triglycerides in the cells was determined by treating licorice phytosome (18 beta-glycyrrhetinic acid), known as a substance that decomposes triglycerides, by concentration (0, 10, 30, 50, and 100 ⁇ M). It was.
- a nile staining assay was performed on liver cancer cell lines treated with licorice phytosomes (18 beta-glycyrrhetinic acid) by concentration (0, 10, 30, 50, and 100 ⁇ M). Some (18 beta-glycyrrhetinic acid) was effective in reducing the content of triglycerides by about 10 to 15%. As a result of increasing the concentration of licorice phytosome (18 beta-glycyrrhetinic acid) in the oil red o staining assay result image was obtained with a decrease in triglyceride (Fig. 3).
- Hepatic cancer cell line HepG 2
- 1 mM oleate and palate mixed (2: 1) free fatty acids to determine the degree to which the triglycerides produced were reduced by the baekrye hydrothermal extract and oil.
- the degree of reduction of the baekpan ethanol extract is slightly weaker than that of the baekpane hydrothermal extract, as shown in FIGS. 6 and 7, the results of the triglycerides in the hepatocytes in the Nile red staining assay and the oil red staining assay results. It was confirmed that the effect of lowering the content is about 10 to 15%.
- MTS assay was performed to confirm the cytotoxicity of the extract of Baekjeok hydrothermal extract according to the present invention.
- the MTS assay was carried out by a conventional experimental method, and the results showed that, even when treated at a high concentration of 500 ⁇ g / ml, the cell viability was hardly changed, as shown in FIG. Confirmed.
- the experimental animals were purchased from Samta Co., 8 weeks old, 120 male C57BL / 6J mice, and were used for the experiment after adapting for 2 weeks. Then, the white piece prepared in (1) of Example 3 while the normal diet control (CON, 10% fat), high fat diet control (HFD, 60% fat), high fat diet by a randomized complete block design Divided into two hot water extract groups (25mg / kg / day, 50mg / kg / day, 100mg / kg / da) and positive control group and high-fat diet and milk thistle extract (100mg / kg / day). Breeding for 9 weeks, water and experimental diet was freely supplied. Mice were used 20 animals in each group.
- the high fat diet and extracts of each group were fed by oral administration for 9 weeks every day. Weight change was measured once a week for 9 weeks, and dietary intake, liver weight and abdominal fat weight were measured. The room temperature was maintained at 22 ⁇ 1 °C, the humidity at 50 ⁇ 5%, and the contrast was adjusted at 12 hour intervals. 10% normal diet and 60% high fat diet were purchased from central laboratory animals.
- Example 1 (1) As a result of confirming the effect of the white migraine hot water extract prepared in Example 1 (1) on the weight gain of the mouse by a high fat diet, in the embodiment 3 (1) of the present invention with a high fat diet compared to the high fat diet group
- the body weight of the group ingesting the prepared white migraine extract showed a significantly lower result.
- 100 mg / kg / day of the white migraine hydrothermal extract administration group showed a significantly low weight gain (Fig. 10A).
- Example 3 (1) As a result of confirming whether the white migraine hot water extract prepared in Example 3 (1) can reduce the liver tissue weight increased by the high fat diet, ingesting both the high fat diet and the white migraine hot water extract of the present invention compared to the high fat diet group The results showed a significant decrease in the weight of liver tissue in one group.
- liver tissue weight of the high fat diet group (HFD) induced by fatty liver by ingesting a high fat diet was significantly increased compared to the liver tissue weight of the normal control group (CON).
- Hepatic tissue weight was significantly lower in the group administered with the extract.
- the weight of the liver tissue in the 100 mg / kg / day of the baekhyeol hydrothermal extract administration group with a high fat diet showed a significantly lower result (Fig. 10B). It is a result supporting the effect of preventing fat accumulation on the liver tissue that is induced.
- the hot-headed hot-water extract of the present invention can reduce the blood ALT and AST increase by the high-fat diet
- the white-head migraine prepared in Example 3 (1) of the present invention together with the high-fat diet compared to the high-fat diet group ALT and AST in the group receiving the hot water extract showed a significant decrease (Fig. 12).
- Example 3 (1) of the present invention can reduce the level of triglyceride, total cholesterol, low density lipoprotein, and free fatty acid in the blood caused by high fat diet, high fat diet
- Significantly increased triglyceride, total cholesterol, low-density lipoprotein, and free fatty acid levels in the group showed a relatively concentration-dependent decrease in the hydrocephalus extract administration group (FIG. 13).
- dietary supplementation of P. pylori hydrothermal extract significantly reduced blood lipid levels and improved non-alcoholic fatty liver induced by high fat diet.
- the baek hyeok hydrothermal extract of the present invention can reduce the blood sugar concentration by the high fat diet
- the blood sugar concentration in the group consuming both the high fat diet and the baekmig hot water extract of the present invention compared to the high fat diet group Significantly decreased concentration dependent (FIG. 14).
- the dietary addition of the baekhyeol hydrothermal extract of the present invention was found to significantly reduce the concentration of sugar in the serum.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Inorganic Chemistry (AREA)
Abstract
Description
Claims (16)
- 백편두(Dolichos lablab Linne) 추출물을 유효성분으로 포함하는 비알콜성 지방간질환의 예방 또는 개선용 건강기능식품 조성물.
- 제1항에 있어서, 상기 백편두 추출물은 열수 추출물인 것을 특징으로 하는 비알콜성 지방간질환의 예방 또는 개선용 건강기능식품 조성물.
- 제1항에 있어서, 상기 백편두 추출물은 조성물 총 중량에 대하여 0.1 내지 10 중량%인 것을 특징으로 하는 비알콜성 지방간질환의 예방 또는 개선용 건강기능식품 조성물.
- 제1항에 있어서, 상기 백편두 추출물은 간 조직의 중성지방 함량을 감소시키는 것을 특징으로 하는 비알콜성 지방간질환의 예방 또는 개선용 건강기능식품 조성물.
- 제1항에 있어서, 상기 비알콜성 지방간질환은 비알콜성 단순성 지방간, 비알콜성 지방간염 및 비알콜성 간경변 중에서 선택된 어느 하나인 것을 특징으로 하는 비알콜성 지방간질환의 예방 또는 개선용 건강기능식품 조성물.
- 백편두(Dolichos lablab Linne) 추출물을 유효성분으로 포함하는 비알콜성 지방간질환의 예방 또는 치료용 약학 조성물.
- 제6항에 있어서, 상기 백편두 추출물은 열수 추출물인 것을 특징으로 하는 비알콜성 지방간질환의 예방 또는 치료용 약학 조성물.
- 제6항에 있어서, 상기 백편두 추출물은 조성물 총 중량에 대하여 0.1 내지 10 중량%인 것을 특징으로 하는 비알콜성 지방간질환의 예방 또는 치료용 약학 조성물.
- 제6항에 있어서, 상기 백편두 추출물은 간 조직의 중성지방 함량을 감소시키는 것을 특징으로 하는 비알콜성 지방간질환의 예방 또는 치료용 약학 조성물.
- 제6항에 있어서, 상기 비알콜성 지방간질환은 비알콜성 단순성 지방간, 비알콜성 지방간염 및 비알콜성 간경변 중에서 선택된 어느 하나인 것을 특징으로 하는 비알콜성 지방간질환의 예방 또는 치료용 약학 조성물.
- 제6항에 있어서, 상기 유효성분 이외에 약학적으로 허용가능한 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로즈 용액, 말토덱스트린 용액, 글리세롤, 에탄올, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 중에서 선택된 1종 이상의 담체를 더 포함하는 것을 특징으로 하는 비알콜성 지방간 예방 또는 치료용 약학 조성물.
- 제6항에 있어서, 상기 유효성분 이외에 약학적으로 허용 가능한 항산화제, 완충액, 정균제, 희석제, 계면활성제, 결합제, 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제 및 보존제 중에서 선택된 1종 이상의 보조제를 더 포함하는 것을 특징으로 하는 비알콜성 지방간 예방 또는 치료용 약학 조성물.
- 백편두(Dolichos lablab Linne) 추출물을 유효성분으로 포함하는 고지방식이에 의해 상승한 체중 또는 혈당의 감소용 조성물.
- 백편두(Dolichos lablab Linne) 추출물을 개체에게 투여하는 단계를 포함하는 비알콜성 지방간질환의 예방 또는 치료방법.
- 백편두(Dolichos lablab Linne) 추출물을 유효성분으로 포함하는 인간을 제외한 동물의 지방간질환의 예방 또는 치료용 수의학적 조성물.
- 백편두(Dolichos lablab Linne) 추출물을 유효성분으로 포함하는 동물의 지방간질환의 예방 또는 개선용 사료 첨가제.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017517080A JP6360972B2 (ja) | 2014-10-13 | 2015-10-13 | 白扁豆抽出物を有効成分として含む非アルコール性脂肪肝疾患の予防または改善のための組成物 |
CN201580053640.1A CN107105742B (zh) | 2014-10-13 | 2015-10-13 | 含有白扁豆提取物作为有效成分的用于预防或改善非酒精性脂肪肝疾病的组合物 |
US15/515,896 US10617732B2 (en) | 2014-10-13 | 2015-10-13 | Composition including extract of Dolichos lablab Linne as active ingredient for preventing or ameliorating non-alcoholic fatty liver disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140137399 | 2014-10-13 | ||
KR10-2014-0137399 | 2014-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016060426A1 true WO2016060426A1 (ko) | 2016-04-21 |
Family
ID=55746914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/010745 WO2016060426A1 (ko) | 2014-10-13 | 2015-10-13 | 백편두 추출물을 유효성분으로 포함하는 비알콜성 지방간질환의 예방 또는 개선용 조성물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10617732B2 (ko) |
JP (1) | JP6360972B2 (ko) |
KR (1) | KR101661145B1 (ko) |
CN (1) | CN107105742B (ko) |
WO (1) | WO2016060426A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190002800A (ko) * | 2017-06-29 | 2019-01-09 | (주)셀아이콘랩 | 지방 분해 효능을 갖는 화장료 조성물 |
JP2020511156A (ja) * | 2016-12-16 | 2020-04-16 | コリア インスティテュート オフ オリエンタル メディスンKorea Institute Of Oriental Medicine | 白扁豆抽出物を有効成分として含有する、二日酔いの解消及びアルコール性胃腸疾患の予防、改善または治療のための組成物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108576313A (zh) * | 2018-04-12 | 2018-09-28 | 河南牧业经济学院 | 一种辅助预防非酒精性脂肪肝的保健茶及制法与检测方法 |
CN109112108A (zh) * | 2018-09-18 | 2019-01-01 | 南京财经大学 | 一种HepG2细胞高脂模型的构建方法及应用 |
KR102251889B1 (ko) * | 2019-01-23 | 2021-05-13 | (주)뉴트리 | 동부, 잠두 또는 제비콩을 함유하는 근 기능 개선 또는 운동수행능력 향상용 조성물 |
CN115025126A (zh) * | 2022-06-23 | 2022-09-09 | 广元市中医医院 | 地龙在制备预防和/或治疗脂肪肝的药物中的用途 |
KR102566370B1 (ko) * | 2022-10-11 | 2023-08-11 | 한국 한의학 연구원 | 콩 추출물을 유효성분으로 함유하는 지방간 질환의 예방, 개선 또는 치료용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030031418A (ko) * | 2001-10-10 | 2003-04-21 | 한국 한의학 연구원 | 혼합 생약재 추출물 및 이를 포함하는 골다공증 예방 또는치료용 약학적 조성물 |
KR100929979B1 (ko) * | 2007-12-04 | 2009-12-04 | 경희대학교 산학협력단 | 항암제 부작용 억제작용과 항암활성을 갖는 신규한 한약재조성물 |
KR20100014098A (ko) * | 2008-08-01 | 2010-02-10 | 주식회사 베네비오 | 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물 |
KR100952188B1 (ko) * | 2008-05-19 | 2010-04-09 | 이수명 | 당화혈색소 강하용 건강 보조 식품 |
KR101088004B1 (ko) * | 2010-11-12 | 2011-12-01 | 동국대학교 산학협력단 | 발효된 한약재를 이용한 정장용 조성물 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100316296B1 (ko) | 1999-11-25 | 2001-12-12 | 오인갑 | 제비콩추출물 및 그 제조방법 |
JP4644787B2 (ja) * | 2003-08-19 | 2011-03-02 | 沖縄県 | リパーゼ阻害活性且つ抗酸化性を有する抗肥満剤 |
CN1927361A (zh) * | 2006-08-11 | 2007-03-14 | 陈福存 | 保肝解酒的营养保健食品及其制备工艺 |
CN101352551A (zh) * | 2007-07-28 | 2009-01-28 | 孙栋梁 | 一种治疗肝病的药物 |
WO2009040824A2 (en) * | 2007-09-24 | 2009-04-02 | Ganga Raju Gokaraju | Anti-adipogenic compositions containing piper betel and dolichos bifloras |
CN101549006B (zh) * | 2008-04-01 | 2011-12-28 | 中国人民解放军军事医学科学院野战输血研究所 | 白扁豆提取物、其提取方法及其在制备抗紫外线损伤制剂中的应用 |
CN101653211B (zh) * | 2009-08-27 | 2012-05-02 | 杨波 | 一种适宜肥胖患者食用的面粉 |
CN101653281B (zh) * | 2009-08-27 | 2012-10-03 | 杨波 | 一种适宜肥胖患者饮用的固体饮料 |
JP2011195503A (ja) * | 2010-03-19 | 2011-10-06 | Shiseido Co Ltd | タンパク質糖化抑制剤 |
CN103384529B (zh) * | 2010-12-21 | 2015-08-12 | 雀巢产品技术援助有限公司 | 适合于控制动物血糖的方法和组合物 |
CN102342418A (zh) * | 2011-08-30 | 2012-02-08 | 马松江 | 一种具有健脾养胃功能的食品组合物及其制备方法 |
CN102872396B (zh) * | 2012-09-13 | 2014-05-07 | 广东海大集团股份有限公司 | 一种仔猪腹泻用复合中草药制剂及其制备方法 |
JP6366279B2 (ja) * | 2013-01-22 | 2018-08-01 | 花王株式会社 | 過活動膀胱の予防又は改善剤 |
WO2015041235A1 (ja) * | 2013-09-17 | 2015-03-26 | 不二製油株式会社 | 生活習慣病治療のための食品素材の使用 |
JP2015057954A (ja) * | 2013-09-17 | 2015-03-30 | 不二製油株式会社 | アディポネクチン分泌促進作用を有する食品及びアディポネクチン分泌促進剤 |
CN103610975A (zh) * | 2013-11-25 | 2014-03-05 | 青岛东颐锦禾农业科技有限公司 | 促消化的牛用药物的制备方法 |
CN104922538A (zh) * | 2015-06-15 | 2015-09-23 | 王杰伟 | 一种用于IgA肾病中药制剂及其制备方法 |
-
2015
- 2015-10-13 WO PCT/KR2015/010745 patent/WO2016060426A1/ko active Application Filing
- 2015-10-13 JP JP2017517080A patent/JP6360972B2/ja active Active
- 2015-10-13 KR KR1020150142482A patent/KR101661145B1/ko active IP Right Grant
- 2015-10-13 US US15/515,896 patent/US10617732B2/en active Active
- 2015-10-13 CN CN201580053640.1A patent/CN107105742B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030031418A (ko) * | 2001-10-10 | 2003-04-21 | 한국 한의학 연구원 | 혼합 생약재 추출물 및 이를 포함하는 골다공증 예방 또는치료용 약학적 조성물 |
KR100929979B1 (ko) * | 2007-12-04 | 2009-12-04 | 경희대학교 산학협력단 | 항암제 부작용 억제작용과 항암활성을 갖는 신규한 한약재조성물 |
KR100952188B1 (ko) * | 2008-05-19 | 2010-04-09 | 이수명 | 당화혈색소 강하용 건강 보조 식품 |
KR20100014098A (ko) * | 2008-08-01 | 2010-02-10 | 주식회사 베네비오 | 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물 |
KR101088004B1 (ko) * | 2010-11-12 | 2011-12-01 | 동국대학교 산학협력단 | 발효된 한약재를 이용한 정장용 조성물 |
Non-Patent Citations (1)
Title |
---|
KOREA INSTITUTE OF ORIENTAL MEDICIN: "The composition for preventing and alleviating nonalcoholic fatty liver disease, containing Semen Dolichoris as an active ingredient", KHIDI BIO BUSINESS FORUM, 10 April 2015 (2015-04-10), Seoul * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020511156A (ja) * | 2016-12-16 | 2020-04-16 | コリア インスティテュート オフ オリエンタル メディスンKorea Institute Of Oriental Medicine | 白扁豆抽出物を有効成分として含有する、二日酔いの解消及びアルコール性胃腸疾患の予防、改善または治療のための組成物 |
US11357812B2 (en) | 2016-12-16 | 2022-06-14 | Korea Institute Of Oriental Medicine | Composition containing Dolichos lablab Linn. extract as active ingredient for easing hangovers, and preventing, alleviating or treating alcoholic gastrointestinal diseases |
KR20190002800A (ko) * | 2017-06-29 | 2019-01-09 | (주)셀아이콘랩 | 지방 분해 효능을 갖는 화장료 조성물 |
KR101960757B1 (ko) | 2017-06-29 | 2019-03-22 | (주)셀아이콘랩 | 지방 분해 효능을 갖는 화장료 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR101661145B1 (ko) | 2016-09-29 |
JP6360972B2 (ja) | 2018-07-18 |
US10617732B2 (en) | 2020-04-14 |
US20170296607A1 (en) | 2017-10-19 |
CN107105742A (zh) | 2017-08-29 |
KR20160043514A (ko) | 2016-04-21 |
CN107105742B (zh) | 2021-01-08 |
JP2017530140A (ja) | 2017-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016060426A1 (ko) | 백편두 추출물을 유효성분으로 포함하는 비알콜성 지방간질환의 예방 또는 개선용 조성물 | |
WO2018110988A1 (ko) | 백편두 추출물을 유효성분으로 함유하는 숙취해소 및 알코올성 위장질환의 예방, 개선 또는 치료용 조성물 | |
WO2015002391A1 (ko) | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 | |
WO2019093739A1 (ko) | 갈색거저리 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물 | |
KR101464337B1 (ko) | 고욤나무 추출물을 유효성분으로 함유하는 항비만용 조성물 | |
WO2016153211A2 (ko) | 감귤류 과피 추출물의 제조방법 및 간 손상 예방, 개선 또는 치료용 조성물 | |
WO2017183902A1 (ko) | 인진, 지유 및 울금 추출물 및 항바이러스제를 유효성분으로 포함하는 간질환 예방 또는 치료용 조성물 | |
KR102085577B1 (ko) | 쌍별귀뚜라미 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물 | |
WO2016190566A9 (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
WO2020091265A1 (ko) | 엘더베리 추출물을 유효성분으로 함유하는 남성 갱년기 증후군의 예방, 치료 또는 개선용 조성물 | |
WO2017082479A1 (ko) | 콩 발아배아 추출물을 포함하는 비만의 예방 또는 치료용 약학 조성물 | |
WO2017082478A1 (ko) | 콩 발아배아 추출물을 포함하는 골다공증의 예방 또는 치료용 약학 조성물 | |
KR102041852B1 (ko) | 벼메뚜기 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물 | |
WO2018190630A1 (ko) | 감태 추출물을 유효성분으로 포함하는 다낭성 난소 증후군 관련 질환의 예방, 개선 또는 치료용 조성물 | |
WO2022146029A1 (ko) | 참깨박 추출물을 포함하는 근육 질환 개선 및 근육량 증대용 조성물 | |
KR101084942B1 (ko) | 천우슬을 이용한 관절염 치료제 | |
WO2012134252A2 (ko) | 마자인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품 | |
JP2014185088A (ja) | 経口組成物、脂肪細胞分化抑制剤および飲食品 | |
WO2020122373A1 (ko) | 자감초 추출물을 유효성분으로 포함하는 남성갱년기 증후군의 예방, 개선 또는 치료용 조성물 | |
WO2018190638A1 (ko) | 쥐눈이콩 추출물을 포함하는 각막 질환의 예방 또는 치료용 조성물 | |
KR20210038099A (ko) | 귀뚜라미 추출물을 포함하는 골질환의 예방, 개선 또는 치료용 조성물 | |
WO2023121314A1 (ko) | 알코올성 간 손상 또는 알코올성 뇌 손상 보호를 위한 아피오스 아메리카나 괴경 추출물의 용도 | |
WO2021085741A1 (ko) | 번행초를 유효성분으로 포함하는 알츠하이머성 치매 개선 또는 치료용 조성물 | |
WO2019004733A2 (ko) | 쌍별귀뚜라미 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물 | |
WO2022225297A1 (ko) | 악액질의 예방, 개선 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15850682 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017517080 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15515896 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15850682 Country of ref document: EP Kind code of ref document: A1 |